ABSTRACT
Objective:To explore the effect of electroencephalographic (EEG) biofeedback combined with buspirone on patients with schizophrenia with anxiety, in order to provide evidence-based reference for clinical treatment.Methods:From January 2018 to January 2020, 80 patients with schizophrenia and anxiety in Jinzhou Kangning Hospital were prospectively selected and divided into the study group and the control group by simple randomization, each group with 40 patients. The control group was given buspirone, and the study group was given EEG biofeedback combined with buspirone. Both were treated for 8 weeks. The efficacy, adverse reactions and the Positive and Negative Symptoms Scale (PANSS) and Hamilton Anxiety Scale (HAMA), the Pittsburgh Sleep Quality Scale (PSQI), Scale of Social Function in Psychosis Inpatients (SSPI), Barthel Index (BI) score, and serum neuroendocrine index thyroid stimulating hormone (TSH), cortisol (Cor) levels before treatment, 4 weeks and 8 weeks after treatment were compared between the two groups.Results:After 8 weeks of treatment, the total effective rate in the study group was higher than that in the control group: 95.0% (38/40) vs. 77.5% (31/40), the difference was statistically significant (χ 2 = 5.16, P<0.05). After 4, 8 weeks of treatment, the PANSS scores in the study group were lower than those in the control group: (49.57 ± 5.65) scores vs. (57.96 ± 6.48) scores, (37.69 ± 4.35) scores vs.(45.07 ± 5.74) scores, the differences were statistically significant ( P<0.05). After 4, 8 weeks of treatment, the HAMA and PSQI scores in the study group were lower than those in the control group, while the SSPI and BI scores were higher than those in the control group, the differences were statistically significant ( P<0.05). After 4, 8 weeks of treatment, the serum TSH and Cor levels in the study group were lower than those in the control group: after 4 weeks of treatment: (2.74 ± 0.84) mU/L vs. (3.35 ± 0.97) mU/L, (276.51 ± 45.96) μg/L vs. (346.42 ± 50.34) μg/L; after 8 weeks of treatment: (2.46 ± 0.72) mU/L vs. (2.82 ± 0.86) mU/L, (197.26 ± 36.84) μg/L vs. (264.19 ± 42.46) μg/L, the differences were statistically significant ( P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment ( P>0.05). Conclusions:EEG biofeedback combined with buspirone can enhance the therapeutic effect by regulating neuroendocrine, reduce the mental symptoms, anxiety and sleep disorders ofschizophrenia patients with anxiety. It can also improve social function and daily life ability, and have high safety.
ABSTRACT
Objective To observe the effects of Wenxinkeli combination use with buspirone on the treatment of cardiac neurosis with ST-T changes.Methods Ninety patients with cardiac neuropathy were randomly divided into placebo group, Wenxin Granule group and combination use group (Wenxinkeli combination use with buspirone),30 cases in each group.The scores of HAMA-14 and HAMD-24 of the three groups were observed at the end of 4 and 8 weeks after treatment when the score of SF-36 and the improvement of ST-T of combination use group were evaluated followed 12 weeks treatment.Results After 4 weeks of treatment, the two scale scores of combination use group and the Wenxinkeli group, including HAMD-24 and HAMA-14, were significantly lower than the placebo group (P<0.05).In comparison with placebo group, the scores of HAMD-24 and the HAMA-14 were significantly lower after 8 weeks treatment.After 12 months of follow-up treatment, the SF-36 scores of combination use group were significantly higher than the other two groups'(P<0.05).Meanwhile, our results showed that the ST-T changes of the combination use group was significantly improved than the other two groups'(P<0.05).Conclusion The treatment of Wenxinkeli combination use with buspirone can significantly decrease anxiety and improve depression in patients with cardiac neurosis, moreover, long-term combination use treatment can distinctly improve patients' quality of life and relieve their physical symptoms of ST-T changes.
ABSTRACT
Objective To evaluate the therapeutic effect and safety of tandospirone and buspirone in the treatment of generalized anxiety disorder.Methods The clinical control study oftandospirone and buspirone in the treatment of generalized anxiety disorder was earched by PubMed,CBM,CNKI,VIP,and Wanfang Data,with deadline from January 2000 to June 2016.Meta-analysis was carried out using RevMan5.0 software to each effect index.Results A total of seven RCTs were included involving 615 patients were identified.Meta-analysis showed that the significant efficiency rate[P=0.34,OR=1.19,95％CI (0.83～1.69)] and HAMA[P=0.80,MD=-0.08,95％CI (-0.72～0.56)] of tandospirone and buspirone had no significant difference.Two groups of adverse drug reactions,dizzy,dry,constipine,insomnia,anorexia,and nausea had no significant difference (P＞0.05).Conclusion The efficacy and adverse reaction oftandospirone and buspirone in the treatment of generalized anxiety disorder are fairly.
ABSTRACT
OBJECTIVE:To observe the efficacy and safety of paroxetine combined with buspirone in the treatment of geriatric depression with anxiety. METHODS:78 patients with geriatric depression with anxiety were randomly divided into control group (39 cases) and observation group (39 cases). Control group received 20-40 mg Paroxetine hydrochloride tablet,within half an hour after breakfast. Observation group additionally received 5-10 mg Buspirone hydrochloride tablet for 3 times. The treatment course for both groups was 8 weeks. Clinical efficacy,HAMD,HAMA and TESS before and after 2,4 and 8 weeks of treatment in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P0.05). CONCLUSIONS:The effi-cacy of buspirone combined with paroxetine is superior to paroxetine alone in the treatment of geriatric depression with anxiety, with better safety.
ABSTRACT
Abstracts: Background: Pain results from complex interactions in peripheral and central synapses.1The majority of current approaches to treating pain are based on the idea that increasing the level of inhibitory drive or tone at key central nervous system (CNS) regions in the pain pathway can alter pain perception2,3,4,5 Lot of neurotransmitters are implicated in it including 5-HT. Thus we were interested If buspirone is having analgesic effect.Our aim was to assess if buspiron has analgesic effect. And if comparative efficacy to drugs used today. Methodology: After appropriate IAEC clearance ,Hotplate , tail flick analgesiometer methods and acetic acid writhing test were employed. Comparative drugs used were amitriptyline and ibuprofen . Buspirone was used in doses of 2,4 ,mg/kg. Results: Our study showed a comparable efficacy of buspirone to ibuprofen in hot plate test while superior efficacy as an analgesic against amitriptyline at dose of 4mg/kg. Conclusion: 5-HT is considered pronociceptive but has shown differential activity in CNS and at peripheral tissues. Buspirone is a partial 5-HT 1A agonist and antianxiety drug. Due to the complex interactions at centers in CNS it was proposed to have analgesic action.Our study evaluated this theory with three analgesic models. Our results show that at doses 2 & 4mg/kg it has comparable effect to ibuprofen 20 mg/kg dose. At the same dose it shows superiority to amitriptyline 40mg/kg. Thus it shows promise in treatment of pain associated with anxiety induced depression or other psychiatric problems.
ABSTRACT
Background: Antidepressants are commonly prescribed drugs. Co-existing disorders like anxiety require therapy with other drugs. The profiles of pharmacological effects of these drugs on central nervous system are influenced by the administration of these drugs either as single or combination. This study is designed to observe the behavioral effects of antidepressants along with the antianxiety agent buspirone in mice. Methods: Four antidepressant drugs belonging to different groups are selected for the study. Amitriptyline, citalopram, venlafaxine and mirtazapine are given orally for 2 weeks. Subsequently, buspirone is added to each antidepressant drug for a period of 3 weeks. The behavioral effects in mice are observed at weekly intervals using photoactometer, rotarod, forced swim test and elevated plus maze. Results: The antidepressant drugs amitriptyline and citalopram showed any change in spontaneous motor activity recorded by photoactometer. In rotarod test venlafaxine showed an increase in values, which showed further increase when buspirone was added. In the forced swim test also, venlafaxine showed a different pattern of effects when compared to other antidepressants. In the elevated plus maze test, the four antidepressants did not show any increase in the time spent in open arm excepting citalopram. Venlafaxine showed an increase in time spent in closed arm. Conclusions: The test drugs do not show any significant depression of central nervous system at the dose used. Venlafaxine showed a different pattern of activity in the rotarod test and swim test. The variation in response is attributed to their effects on central neurotransmitter.
ABSTRACT
AIM@#Stress is recognized to precipitate anxiety and related psychological problems characterized by a wide range of biochemical and behavioral changes. The present study was carried out to investigate the protective effects of melatonin and buspirone, and their combination, against six hours immobilization stress-induced, anxiety-like behavioral and oxidative damage in mice.@*METHOD@#Male Laca mice were pre-treated with melatonin (2.5, 5 mg·kg(-1)), buspirone (5, 10 mg·kg(-1)), and their combination for consecutive five days. On the 6(th) day, animals were immobilized for six hours, and thereafter various behavioral tests were performed followed by biochemical tests.@*RESULTS@#Immobilization stress significantly impaired body weight, locomotor activity, and caused anxiety-like behavior, along with increased oxidative damage. Pretreatment with melatonin and buspirone significantly improved the loss in body weight and locomotor activity, attenuated anxiety-like behavior (in both the mirror chamber and plus maze performance tasks), further restored the levels of brain total proteins, and caused antioxidant-like effects, as evidenced by reduced lipid peroxidation, nitrite concentration, and restoration of reduced glutathione and catalase activity, as compared to control animals. In addition, combination of melatonin (2.5, 5 mg·kg(-1)) with buspirone (5 mg·kg(-1)) significantly potentiated their protective effects, as compared to their effects individually.@*CONCLUSION@#The present study suggests that melatonin potentiates the beneficial effect of buspirone against immobilization stress-induced, anxiety-like behavioral and oxidative damage in mice possibly by involving a serotonergic mechanism.
Subject(s)
Animals , Male , Anti-Anxiety Agents , Pharmacology , Therapeutic Uses , Antioxidants , Pharmacology , Therapeutic Uses , Anxiety , Drug Therapy , Behavior, Animal , Buspirone , Pharmacology , Therapeutic Uses , Immobilization , Psychology , Melatonin , Pharmacology , Therapeutic Uses , Mice, Inbred Strains , Oxidative Stress , Stress, Psychological , Drug TherapyABSTRACT
Sleep deprivation can lead to various alterations at physiological and psychological levels such as EEG changes, metabolic changes, irritation, blurred vision, memory lapses, hallucinations, psychosis and can even lead to death. Treatment still remains a challenge as hypnotics are associated with side effects. The objective of the present study was to investigate the protective effects of melatonin and buspirone and their combinations against the biochemical and behavioral alterations induced by 48 hrs sleep deprivation in mice. Pretreatment with melatonin (2.5 mg/kg and 5 mg/kg), buspirone (5 mg/kg and 10 mg/kg), and melatonin (2.5, 5 mg/kg) in combination with buspirone (5 mg/kg) showed significant improvement in behavioral parameters such as increase in body weight, increase in locomotor activity, and reduction in anxiety like behavior. Biochemical parameters estimation also revealed similar results such as significant attenuation of lipid peroxidation and nitrite concentration and significant elevation of glutathione and catalase levels following treatment with melatonin (2.5, 5 mg/kg) and buspirone (5,10 mg/kg) and melatonin (2.5, 5 mg/kg) in combination with buspirone (5 mg/kg) as compared to their effect per se. Thus, preliminary findings suggest the protective effect of melatonin and buspirone and their combinations against sleep deprivation and associated alterations.
ABSTRACT
A buspirona é o primeiro fármaco da classe das azapironas e a única comercializada no Brasil. O objetivo do presente trabalho foi conduzir uma revisão de literatura sobre os aspectos farmacológicos da buspirona, bem como demonstrar seus efeitos anticonvulsivantes e neuroprotetores no modelo de convulsão induzido por pilocarpina. Para tanto, foi realizada uma revisão da literatura usando as palavras-chaves buspirone, action mechanism, pharmacokinetics, indications, adverse effects, nomenclature e structure, por intermédio do MEDLINE e LILACS, bem como foram inseridos os resultados experimentais encontrados em camundongos pré-tratados com buspirona no modelo de convulsão induzido por pilocarpina. A busca incluiu todos os artigos completos, resumos, estudos de caso, pré-clínicos e clínicos nos idiomas português e inglês compreendidos entre os anos de 1982 e 2010. Com base na revisão, pode se perceber que ainda existem muitas questões sem respostas sobre a farmacologia da buspirona. Somente a descrição do mecanismo de ação é insuficiente para explicar todos os efeitos produzidos pela buspirona. Além disso, em nossos estudos farmacológicos demonstramos que a buspirona apresenta efeitos anticonvulsivantes e neuroprotetores em camundongos no modelo de convulsão induzido por pilocarpina. Existem poucas informações na literatura sobre o mecanismo de ação que explicaria os efeitos adversos da buspirona, bem como suas propriedades anticonvulsivantes e neuroprotetoras. Dessa forma, são necessários mais estudos para fornecer as informações necessárias, bem como para esclarecer as suas propriedades farmacológicas, contribuindo com o conhecimento dos profissionais, a fim de prevenir os efeitos adversos durante o tratamento clínico com a buspirona.
Buspirone was the first drug in the class of azapirones and is the only one marketed in Brazil. The objective of this study was to conduct a literature review on the pharmacology of buspirone, as well as to demonstrate its neuroprotective and anticonvulsant effects in the model of seizures induced by pilocarpine. To this end, we employed the keywords buspirone, action mechanism, pharmacokinetics, indications, adverse effects, nomenclature and structure to perform a search of the literature, through MEDLINE and LILACS, and inserted the experimental results obtained in mice pretreated with buspirone in the model of seizures induced by pilocarpine. The search included all full articles, abstracts, case studies, pre-clinical and clinical studies in Portuguese and English, between the years 1982 and 2010. The review revealed that there are still many unanswered questions about the pharmacology of buspirone. A description of the mechanism of action alone is insufficient to explain all the effects produced by buspirone. Moreover, our pharmacological studies have shown that buspirone has anticonvulsant and neuroprotective effects in a mouse model of seizures induced by pilocarpine. There is little information in the literature about mechanisms that would explain either the adverse effects of buspirone or its anticonvulsant and neuroprotective properties. Thus, further studies are needed to provide the necessary information, as well as to clarify its pharmacological properties, in order to enable professionals to prevent adverse effects during clinical treatment with buspirone.
Subject(s)
Buspirone/adverse effects , Buspirone/pharmacokinetics , Buspirone/pharmacologyABSTRACT
CONTEXTO: Crises epilépticas induzidas por pilocarpina podem produzir alterações histopatológicas em muitas regiões cerebrais como consequência da produção excessiva de radicais livres.OBJETIVO: O objetivo do presente estudo foi avaliar o efeito antioxidante da buspirona no modelo de epilepsia induzida por pilocarpina.MATERIAL E MÉTODOS: Quarenta e oito animais foram divididos em quatro grupos. O primeiro grupo foi tratado com solução salina 0,9% (Controle). O segundo grupo foi tratado com pilocarpina 400 mg/kg (P400). Por sua vez, o terceiro grupo foi tratado com buspirona 5 mg/kg (BUSP) durante 14 dias consecutivos. Já os animais do quarto grupo foram tratados com buspirona durante 14 dias consecutivos, e, 30 minutos após a última administração dela, os camundongos receberam P400 (BUSP + P400).RESULTADOS: Durante o período do tratamento não se observaram sinais de toxicidade e nenhuma morte entre os animais tratados com buspirona. Em nosso estudo o grupo tratado com P400 demonstrou um aumento significativo da produção de nitrito e nos níveis de peroxidação lipídica após as crises epilépticas. Por outro lado, no hipocampo dos animais que receberam o pré-tratamento com buspirona e após 30 minutos receberam P400, foi observada redução significativa nos níveis de peroxidação lipídica (65%) e nitrito (85%), bem como aumento na atividade da enzima superóxido dismutase.CONCLUSÃO: O pré-tratamento com BUSP aumentou a latência para primeira crise epiléptica e diminuiu a taxa de mortalidade e o número de animais que apresentaram crise epiléptica e que progridem para o estado de mal epiléptico. Além disso, apresentou efeitos anticonvulsivantes associados com a redução do estresse oxidativo hipocampal no modelo de epilepsia induzida por pilocarpina.
BACKGROUND: Pilocarpine-induced seizures can cause pathological changes in many brain regions as a result of excessive production of free radicals.OBJECTIVE: The objective of this study was to evaluate the antioxidant effect of buspirone in the epilepsy model induced by pilocarpine.MATERIAL AND METHODS: Forty-eight animals were divided into four groups. The first group was treated with saline 0.9% (control); the second group received pilocarpine 400 mg/kg (P400); the third group was treated with buspirone 5 mg/kg (BUSP) for 14 consecutive days and animals in the fourth group were treated with buspirone for 14 consecutive days, and 30 minutes after the last buspirone administration were administered with P400 (BUSP + P400).RESULTS: No toxicity signs or death were observed in buspirone-treated animals. P400 group showed a significant increase in nitrite production and lipid peroxidation after seizures. Moreover, reduction in both the lipid peroxidation level (65%) and nitrite content (85%) as well as an increase in superoxide dismutase activity was detected following P400 injection in the hippocampus of buspirone-pretreated mice.DISCUSSION: Pretreatment with BUSP increased latency to first seizure, decreased the mortality rate and number of animals that presented seizures and progression to status epilepticus, showing potent anticonvulsant effects associated with reduction of hippocampal oxidative stress.
Subject(s)
Animals , Male , Mice , Models, Animal , Antioxidants/therapeutic use , Buspirone/therapeutic use , Seizures/chemically induced , Epilepsy/chemically induced , Oxidative Stress , Pilocarpine/adverse effectsABSTRACT
@#Objective To compare the efficacy and safety of mirtazapine and buspirone on panic disorder.Methods 86 cases with panic disorder were divided into two groups: the mirtazapine(30～60 mg/d) group and the buspirone(15～30 mg/d) group.Hamilton Anxiety Scale(HAMA) was adopted to evaluate the efficacy.Safety was evaluated with Treatment Emergent Symptom Scale(TESS),laboratorial and physical examination.Results The effective rate of mirtazapine group and buspirone group was 90.7% and 83.7% respectively 8 weeks after treatment(χ2=1.17,P>0.05).The scores of HAMA of the mirtazapine group decreased more than that of the buspirone group 1 or 2 weeks after treatment(tt=2.94,P<0.01 and t=2.49,P<0.05 respectively).At the end of wk,But there was not significant difference between two groups 4 or 8 weeks after treatment(P>0.05).Some mild side-effects were observed in both groups.Conclusion Mirtazapine shows a similar effect to buspirone and takes effect earlier on panic disorder.
ABSTRACT
@#Objective To observe the effect of buspirone on ataxia symptom after stroke.Methods 30 patients with ataxia after stroke were treated with buspirone,other 30 patients without buspirone as controls.Before and after treatment,they were assessed with ataxia-scale.Results The buspirone can significantly improve the ataxia of patients with stroke compared with the controls(P<0.01).Conclusion Short-term treatment with buspirone can improve the ataxia symtoms after stroke.
ABSTRACT
OBJECTIVE:To prepare buspiron hydrochloride sustained-release tablets and to study its release characterization in vitro and the factors affecting drug release.METHODS:Buspiron hydrochloride sustained-release tablets were prepared with hydroxypropyl methylcellulose(HPMC)as hydrophilic gel-matrix material and ethylcellulose(EC)as retarder by wet granulation.The impacts of releasing transmitters,contents of HPMC and EC,and viscosity on the drug release in vitro of the tablets were studied.RESULTS:For the prepared sustained release tablets,the 24h drug release amount was over 90%,and the drug release curve conformed to Higuchi equation.The more contents of HPMC and EC and the higher viscosity of HPMC in the tablets,the slower drug release velocity was obtained;but the viscosity of EC and the releasing transmitters had no significant impacts on the drug release velocity.CONCLUSION:With HPMC and EC as matrix materials,the 24h continuous drug release is available for buspirone hydrochloride sustained-tablets.
ABSTRACT
BACKGROUND: Migraine is commonly associated with anxiety disorder. However, whether anxiolytic medicine or changes in anxiety levels affect the migraine attack is unclear. Buspirone, the agonist for 5-HT1A receptor, is effective in treating generalized anxiety disorder. In this study, we attempted to test the efficacy of buspirone for migraine combined with anxiety disorder. METHODS: 111 outpatients aged 20 to 70 years (mean, 46.4; SD, 12.8), were analyzed. The diagnosis of migraine was made according to the HIS (International Headache Society) criteria, and the level of anxiety was rated by the Hamiton Anxiety Rating Scale (HAM-A). The migraineurs were randomly assigned to treatment with either buspirone (15 mg/day) or placebo for 6 weeks. The efficacy variables included changes in headache frequency, headache intensity, Headache Index, Headache Management Self-Efficacy Scale (HMSE), Headache Disability Inventory (HDI), and the Hamilton Anxiety Rating Scale (HAM-A). The correlation between headache improvement and the anxiolytic effect were analyzed. RESULTS: Headache frequency showed a 43.3% reduction (from 6.7/2 weeks to 3.8/2 weeks) in the buspirone-treated group, whereas a 10.3% reduction (from 6.8 to 6.1/2 weeks) in the placebo group. The Headache Index, HDI, and HAM-A were also significantly lowered in buspirone-treated patients than in placebo-treated patients. However, the headache intensity or the HMSE score were not changed. Correlation analysis between the change of Headache Index and that of HAM-A revealed no significant association. CONCLUSIONS: Buspirone is an effective prophylactic agent in migraine combined with anxiety disorder. This prophylactic effect is not secondary to the anxiolytic effect. This suggests that the agonistic action for 5-HT1A is primarily effective in migraine prophylaxis.
Subject(s)
Humans , Anti-Anxiety Agents , Anxiety Disorders , Anxiety , Buspirone , Diagnosis , Headache , Migraine Disorders , Outpatients , Receptor, Serotonin, 5-HT1AABSTRACT
OBJECTIVE:To establish a HPLC method for determination of the concentration of Buspirone in serum.MET_ HODS:The chromatographic system consisted of ZORBA SB-C 18 column and mobile phase of methanol-acetonitrile-water-0.1mol/L NaAC buffer solution(pH4.5)(10∶38∶51∶1),with a detection wavelength of237nm,and the content was calcu?lated by peak area internal standard method.RESULTS:The linear range of Buspirone was1～80ng/ml,r=0.9979.CONCL_ USION:This method is simple and accurate for determination of Buspirone in serum.
ABSTRACT
OBJECTIVES: The purpose of this study was to evaluate the prolactin and cortisol responses to 5-HT 1A receptor activation by buspirone in alcoholics. METHODS: The subjects were twenty two male alcoholic patients meeting the DSM-IV criteria for alcohol dependency and abstaining for more than 3 months. Patients were free from overt anxiety and depressive symptoms. Controls were fifteen male normal volunteers, with no psychiatric and medical illness. Blood samples for the measurement of serum cortisol and prolactin levels were drawn 0, 30, 60, 90, 120, 150 minutes after oral administration of 30mg buspirone hydrochloride at 9:00 a.m. RESULTS: The baseline cortisol levels were not significantly different between alcoholics and controls. Serum cortisol levels of controls after buspirone administration were significantly increased over time(p<0.01), but those of alcoholics did not increased. After 60 minutes following buspirone administration, cortisol levels were significantly lower in alcoholics than in controls(p<0.05). Prolactin responses to buspirone were not significantly different between the two groups. CONCLULSION: Our results suggested that 5-HT 1A receptor function is decreased in alcoholic patients.
Subject(s)
Humans , Male , Administration, Oral , Alcoholics , Alcoholism , Anxiety , Buspirone , Depression , Diagnostic and Statistical Manual of Mental Disorders , Healthy Volunteers , Hydrocortisone , Prolactin , SerotoninABSTRACT
Objetivo - Avaliar a eficácia e a segurança do cloridato de buspirona em pacientes de clínica cardiológica com manifestaçöes de ansiedade generalizada. Métodos - Cinquenta pacientes ambulatoriais de clínica cardiológica com sintomas psicossomáticos cardiovasculares foram tratados com cloridato de buspirona na dose inicial de 5mg 3 vezes ao dia, por 6 semanas. Resultado - Os resultados obtidos foram considerados bons em 76//, regulares em 18// e ineficazes em 6// dos casos. Treze pacientes (26//) relatarm pelo menos uma reaçäo adversa, os efeitos colaterais relatados foram sonolência, cefaléia, flatulência, zumbido, congestäo nasal e boca seca. Näo houve necessidade de interrupçäo do tratamento. Conclusäao - O cloridato de buspirona é uma alternativa válida no tratamento da ansiedade patológica em pacientes onde o estado de vigilância e habilidade psicomotora devem ser preservados
Purpose - To evaluate the efficacy of buspirone hydrochloride in patients of the cardiologic clinic with generalized anxiety. Méthods - Fifty out-patients with psychossomatic cardiovascular symptons in cardialogy were treated for six weeks with initial dose of 5mg of baspirone hydrochloride t.i.d. Results - The results obtained were good in 76% of the patients, foir in 18% and ineffective in 6% of the cases. Thirteen patients (26%) reported at least one adverse event, the side effects reported were: somnolence, headache, flatulence, tinnitus, nasal congestion and dry mouth. No interruption of the treatment was needed. Conclusion - Buspirone hydrochloride is a valid alternative for treating pathological anxiety in patients in which the state of alertness and good psychomotor skills must be preserved
Subject(s)
Humans , Male , Female , Anxiety/drug therapy , Buspirone/therapeutic use , Cardiovascular Diseases/psychology , Psychophysiologic Disorders/drug therapy , Buspirone/administration & dosage , Treatment Outcome , Ambulatory CareABSTRACT
AIM:To evaluate the efficacy of Bailemian Capsule(bulbus lilii,Radix et rhizome seu acanthopanacis senticosi caulis,Caulis polygoni multiflori,Flos albiziae,Concha margaritifera) in combination with buspirone in generalised anxiety disease. METHODS:Seventy-seven patients with generalized anxiety disease were randomly assigned to two groups:Bailemian Capsule in combination with buspirone in the treated group; buspirone alone in the control group. A period of six weeks was one treatment course in each group. The clinical effectiveness was evaluated according to HAMA reactions. RESULTS:HAMA score(P